Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceedingHAE CHAPTER-1, Phase 2 prophylactic study of PHVS416 for prevention of HAE attacks, on-track to initiate in...
May 12, 2021 07:00 ET | Source: Pharvaris N.V.

Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer

Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral products for HAE patients ZUG, Switzerland, May 12, 2021 ...
April 29, 2021 16:15 ET | Source: Pharvaris N.V.

Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights

RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAEOpen IND for the prophylactic evaluation of PHVS416Strong pre-IPO cash and cash equivalents balance of €98.6...
April 21, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416

ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
March 04, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris to Participate in BioCapital Europe

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
February 26, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
February 19, 2021 10:00 ET | Source: Pharvaris N.V.

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting

ZUG, Switzerland, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative...
February 09, 2021 16:05 ET | Source: Pharvaris N.V.

Pharvaris Announces Closing of Initial Public Offering

ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
February 04, 2021 20:08 ET | Source: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized Initial Public Offering

ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative...